 Vaccine adjuvants are compounds used to increase specific immune responses to antigens, but have minimal toxicity or lasting immune effects on their own. This study investigates the use of dendritic cells as an adjuvant for NY-ESO-1 and Melan-AMART-1 peptides compared to Montanide in study subjects with melanoma in complete clinical remission. 